SCI时时刷

search
+
The promise and challenges of combination therapies with antibody-drug conjugates in solid tumors
The promise and challenges of combination therapies with antibody-drug conjugates in solid tumors
Antibody-drug conjugates (ADCs) represent an important class of cancer therapies that have revolutionized the treatment pa...
Bone marrow graft versus peripheral blood graft in haploidentical hematopoietic stem cells transplantation: a retrospective analysis in1344 patients of SFGM-TC registry
Bone marrow graft versus peripheral blood graft in haploidentical hematopoietic stem cells transplantation: a retrospective analysis in1344 patients of SFGM-TC registry
The use of peripheral blood (PB) or bone marrow (BM) stem cells graft in haploidentical hematopoietic stem cell transplant...
Vaccines: a promising therapy for myelodysplastic syndrome
Vaccines: a promising therapy for myelodysplastic syndrome
Myelodysplastic neoplasms (MDS) define clonal hematopoietic malignancies characterized by heterogeneous mutational and cli...
cAMP-PKA/EPAC signaling and cancer: the interplay in tumor microenvironment
cAMP-PKA/EPAC signaling and cancer: the interplay in tumor microenvironment
Cancer is a complex disease resulting from abnormal cell growth that is induced by a number of genetic and environmental f...
Nanobody-based trispecific T cell engager (Nb-TriTE) enhances therapeutic efficacy by overcoming tumor-mediated immunosuppression
Nanobody-based trispecific T cell engager (Nb-TriTE) enhances therapeutic efficacy by overcoming tumor-mediated immunosuppression
T cell engagers (TCEs) have been established as an emerging modality for hematologic malignancies, but solid tumo...
Reactive oxygen species (ROS) scavenging biomaterials for anti-inflammatory diseases: from mechanism to therapy
Reactive oxygen species (ROS) scavenging biomaterials for anti-inflammatory diseases: from mechanism to therapy
Inflammation is a fundamental defensive response to harmful stimuli, but the overactivation of inflammatory responses is a...
Novel research and future prospects of artificial intelligence in cancer diagnosis and treatment
Novel research and future prospects of artificial intelligence in cancer diagnosis and treatment
Research into the potential benefits of artificial intelligence for comprehending the intricate biology of cancer has grow...
Genitourinary cancers updates: highlights from ASCO 2023
Genitourinary cancers updates: highlights from ASCO 2023
Significant scientific advances in immunotherapy and targeted therapy approaches have improved clinical outcomes and incre...
Direct inhibition of dioxygenases TET1 by the rheumatoid arthritis drug auranofin selectively induces cancer cell death in T-ALL
Direct inhibition of dioxygenases TET1 by the rheumatoid arthritis drug auranofin selectively induces cancer cell death in T-ALL
T-cell acute lymphoblastic leukemia (T-ALL) is a type of hematologic tumor with malignant proliferation of hematopoietic p...
Retraction Note: The LINC00623/NAT10 signaling axis promotes pancreatic cancer progression by remodeling ac4C modification of mRNA
Retraction Note: The LINC00623/NAT10 signaling axis promotes pancreatic cancer progression by remodeling ac4C modification of mRNA
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, whi...
Correction: Acylglycerol kinase promotes tumour growth and metastasis via activating the PI3K/AKT/GSK3β signalling pathway in renal cell carcinoma
Correction: Acylglycerol kinase promotes tumour growth and metastasis via activating the PI3K/AKT/GSK3β signalling pathway in renal cell carcinoma
Qian Zhu, Ai-Lin Zhong and Hao Hu have contributed equally to this work.State Key Laboratory of Oncology in Southern China...
Outcomes of patients with secondary central nervous system lymphoma following CAR T-cell therapy: a multicenter cohort study
Outcomes of patients with secondary central nervous system lymphoma following CAR T-cell therapy: a multicenter cohort study
Chimeric antigen receptor T-cell therapy (CAR-T) has been successful in treating relapsed/refractory B-cell lymphomas. How...
Reprogramming T cell differentiation and exhaustion in CAR-T cell therapy
Reprogramming T cell differentiation and exhaustion in CAR-T cell therapy
T cell differentiation is a highly regulated, multi-step process necessary for the progressive establishment of effector f...
CRISPR screening in hematology research: from bulk to single-cell level
CRISPR screening in hematology research: from bulk to single-cell level
The CRISPR genome editing technology has revolutionized the way gene function is studied. Genome editing can be achieved i...
Correction: Non-T-depleted haploidentical transplantation with post-transplant cyclophosphamide in patients with secondary versus de novo AML in first complete remission: a study from the ALWP/EBMT
Correction: Non-T-depleted haploidentical transplantation with post-transplant cyclophosphamide in patients with secondary versus de novo AML in first complete remission: a study from the ALWP/EBMT
Division of Hematology, Sheba Medical Center, Tel Hashomer, IsraelArnon NaglerEBMT Paris Study Office, Department of Haema...
Correction: Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy
Correction: Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, whi...
Genomic profiling of post-transplant lymphoproliferative disorders using cell-free DNA
Genomic profiling of post-transplant lymphoproliferative disorders using cell-free DNA
Diagnosing post-transplant lymphoproliferative disorder (PTLD) is challenging and often requires invasive procedures. Anal...
Lipid metabolic reprogramming in tumor microenvironment: from mechanisms to therapeutics
Lipid metabolic reprogramming in tumor microenvironment: from mechanisms to therapeutics
Lipid metabolic reprogramming is an emerging hallmark of cancer. In order to sustain uncontrolled proliferation and surviv...
CT041 CAR T cell therapy for Claudin18.2-positive metastatic pancreatic cancer
CT041 CAR T cell therapy for Claudin18.2-positive metastatic pancreatic cancer
Pancreatic cancer lacks effective therapy. Here, we reported two metastatic pancreatic cancer patients administrated with ...
Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy
Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy
In one decade, immunotherapy based on immune checkpoint blockades (ICBs) has become a new pillar of cancer treatment follo...
Recent advances in targeted strategies for triple-negative breast cancer
Recent advances in targeted strategies for triple-negative breast cancer
Triple-negative breast cancer (TNBC), a highly aggressive subtype of breast cancer, negatively expresses estrogen receptor...
Advances in single-cell RNA sequencing and its applications in cancer research
Advances in single-cell RNA sequencing and its applications in cancer research
Cancers are a group of heterogeneous diseases characterized by the acquisition of functional capabilities during the trans...
Beyond Bruton’s tyrosine kinase inhibitors in mantle cell lymphoma: bispecific antibodies, antibody–drug conjugates, CAR T-cells, and novel agents
Beyond Bruton’s tyrosine kinase inhibitors in mantle cell lymphoma: bispecific antibodies, antibody–drug conjugates, CAR T-cells, and novel agents
Mantle cell lymphoma is a B cell non-Hodgkin lymphoma (NHL), representing 2–6% of all NHLs and characterized by over...
Phase I study evaluating the Fc-optimized FLT3 antibody FLYSYN in AML patients with measurable residual disease
Phase I study evaluating the Fc-optimized FLT3 antibody FLYSYN in AML patients with measurable residual disease
About half of AML patients achieving complete remission (CR) display measurable residual disease (MRD) and eventually rela...
Challenges and new technologies in adoptive cell therapy
Challenges and new technologies in adoptive cell therapy
Adoptive cell therapies (ACTs) have existed for decades. From the initial infusion of tumor-infiltrating lymphocytes to th...
Retraction Note: HNF4A-AS1/hnRNPU/CTCF axis as a therapeutic target for aerobic glycolysis and neuroblastoma progression
Retraction Note: HNF4A-AS1/hnRNPU/CTCF axis as a therapeutic target for aerobic glycolysis and neuroblastoma progression
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, whi...
Synergistic efficacy of simultaneous anti-TGF-β/VEGF bispecific antibody and PD-1 blockade in cancer therapy
Synergistic efficacy of simultaneous anti-TGF-β/VEGF bispecific antibody and PD-1 blockade in cancer therapy
Recently, therapeutic antibodies against programmed cell death 1 (PD-1) and its ligand (PD-L1) have exerted potent antican...
New immunotherapy strategies for patients with sarcomas: highlights from the 2023 ASCO annual meeting
New immunotherapy strategies for patients with sarcomas: highlights from the 2023 ASCO annual meeting
Immunotherapy has revolutionized cancer treatment, but currently, immuno-oncology agents have not been approved for patien...
Bispecific antibodies targeting BCMA, GPRC5D, and FcRH5 for multiple myeloma therapy: latest updates from ASCO 2023 Annual Meeting
Bispecific antibodies targeting BCMA, GPRC5D, and FcRH5 for multiple myeloma therapy: latest updates from ASCO 2023 Annual Meeting
Several bispecific antibodies (bsAbs) targeting BCMA, GPRC5D, and FcRH5 are in clinical trials for heavily pretreated mult...
CD20 × CD3 bispecific antibodies for lymphoma therapy: latest updates from ASCO 2023 annual meeting
CD20 × CD3 bispecific antibodies for lymphoma therapy: latest updates from ASCO 2023 annual meeting
Multiple bispecific antibodies (bsAbs) have been approved for cancer immunotherapy. Several CD20 × ...
阅读更多
format_indent_increase